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Abstract
Background
Irreversible Electroporation (IRE) is a novel image-guided tissue ablation technology that
induces cell death via very short but strong pulsed electric fields. IRE has been shown to
have preserving properties towards vessels and nerves and the extracellular matrix. This
makes IRE an ideal candidate to treat prostate cancer (PCa) where other treatment modali-
ties frequently unselectively destroy surrounding structures inducing severe side effects like
incontinence or impotence. We report the retrospective assessment of 471 IRE treatments
in 429 patients of all grades and stages of PCa with 6-year maximum follow-up time.
Material and findings
The patient cohort consisted of low (25), intermediate (88) and high-risk cancers (312).
All had multi-parametric magnetic resonance imaging, and 199 men had additional 3D-
mapping biopsy for diagnostic work-up prior to IRE. Patients were treated either focally
(123), sub-whole-gland (154), whole-gland (134) or for recurrent disease (63) after previ-
ous radical prostatectomy, radiation therapy, etc. Adverse effects were mild (19.7%),
moderate (3.7%) and severe (1.4%), never life-threatening. Urinary continence was pre-
served in all cases. IRE-induced erectile dysfunction persisted in 3% of the evaluated
cases 12 months post treatment. Mean transient IIEF-5-Score reduction was 33% within
12-month post IRE follow-up and 15% after 12 months. Recurrences within the follow-up
period occurred in 10% of the treated men, 23 in or adjacent to the treatment field and 18
outside the treatment field (residuals). Including residuals for worst case analysis, Kaplan
Maier estimation on recurrence rate at 5 years resulted in 5.6% (CI95: 1.8–16.93) for
Gleason 6, 14.6% (CI95: 8.8–23.7) for Gleason 7 and 39.5% (CI95: 23.5–61.4) for Glea-
son 8–10.
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Conclusion
The results indicate comparable efficacy of IRE to standard radical prostatectomy in terms
of 5-year recurrence rates and better preservation of urogenital function, proving the safety
and suitability of IRE for PCa treatment. The data also shows that IRE, besides focal therapy
of early PCa, can also be used for whole-gland ablations, in patients with recurrent PCa,
and as a problem-solver for local tumor control in T4-cancers not amenable to surgery and
radiation therapy anymore.
Introduction
The incidence of prostate cancer (PCa) is increasing worldwide, with an estimated 1.1 million
new cases in 2012 [1]. Established PCa-treatments like radical prostatectomy (RPE) or radia-
tion therapy (RT) aim to treat the whole prostate, which is associated with side effects such as
impotence, incontinence and potential damage to the rectum and bladder [2][3], whilst at best
providing only moderate survival benefits compared to active surveillance [4]. It has recently
been shown that the largest PCa lesion with the highest tumor grade predominantly influences
the progression of disease [5][6], suggesting that treatment of this index lesion alone would be
highly effective [7][8]. Focal thermal therapies such as Cryosurgery, Radiofrequency Ablation
(RFA) or High Intensity Focal Ultrasound (HIFU) have gained ground as minimally invasive
alternatives to established therapies [9][10]. In comparison, Irreversible Electroporation (IRE),
a novel tissue ablation technology, has the advantage of being non-thermal with elements of
tissue selectivity [11], which significantly reduces toxicity on vital anatomical structures sur-
rounding the malignancy. Because of these properties, IRE might become a standard therapy
for PCa, and further, a problem solver for advanced T4-cancers for which there are few other
treatment options and/or only treatable with resulting permanent damage.
To date, six studies with smaller patient cohorts have been published on IRE of PCa [12–
17]. However, no larger case series were published to the best of our knowledge. There is an
ongoing multi-center register trial (NCT02255890). This publication presents the retrospective
evaluation of 471 IRE treatments, discussing feasibility, safety, toxicity, functional and onco-
logical outcomes.
Patients and methods
Patient selection and ethical approval statement
Men with prostate cancer who would potentially benefit from IRE-treatment of their PCa and
who refused all types of standard therapy were included, with the primary goal of significant
tumor mass reduction, and complete local tumor ablation if achievable. Patients with all stages
of disease were included. Patients unfit for total intravenous anesthesia and patients with defi-
brillators were excluded because there was no statement from the manufactures regarding the
safety in conjunction with pulsed electrical field treatments.
All patients underwent meticulous informed consent about the nature of their disease, the
prognosis, the established treatment options according to the S3-guidelines for the treatment
of PCa issued by the German Urological Society, the technique and experimental nature of the
IRE treatment and the details of the diagnostic work-up concerning the localization of cancer
foci in their prostate. As the data analysis is retrospective, a formal consent specific to the data
analyzed, summarized and presented here, is not required. Each treatment was personalized
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according to the patient’s individual needs and wishes (individual medical treatment). Data
collection was purely retrospective. No treatment was adapted to suit scientific purposes.
Patient cohort
Between May 2011 and October 2016 471 tissue ablation procedures in 429 patients with PCa
were performed, using IRE (NanoKnife, AngioDynamics Inc., USA). Table 1 summarizes
patient demographics, cancer grade and stage. Seventy patients had had PCa related treat-
ments prior to IRE: Sixteen patients had undergone radical prostatectomy (RPE), twenty-three
had had radiation therapy (RT), 5 had had both. Seventeen patients had undergone a transure-
thral resection of the prostate (TURP), 8 had been treated with High-Intensity Focused Ultra-
sound (HIFU), two of which had had the procedure performed twice. The majority (N = 29) of
those with previous treatments had undergone androgen deprivation therapy (ADT).
Diagnostic work-up
All patients underwent multi-parametric Magnetic Resonance Imaging (mpMRI) at least once
prior to IRE [18], except one patient with a cardiac pace maker. Apart from nine, all patients
(N = 420) had histo-pathological confirmation of PCa (Table 1). Almost half of the patients
(N = 199) underwent 3D-mapping biopsy, either as the initial type of biopsy or secondarily to
determine the spacial distribution of PCa in their prostate; the technique employed was similar
to the one described in the paper of Onik et al. [19] and is further described in S1 Text.
Procedures
The IRE electrodes (AngioDynamics Inc., USA) were manually inserted through the perineum
under ultrasound guidance without a brachytherapy grid, as previously described [20]. The
IRE-field was planned in a way that it exceeded the macroscopic tumor extent by at least 8mm
towards the center of the prostate, often more, when the additional ablation volume associated
with this was deemed not to cause any additional adverse effects and by increasing the distance
between electrode pairs provide a more advantageous, larger ablation field. Towards the cap-
sule the electrodes were, whenever possible, placed within a couple millimeters inside the pros-
tatic capsule. The treatment field geometry was estimated primarily using the treatment field
estimator provided by the IRE generator (NanoKnife, Angiodynamics, European version) and
results from finite element simulations as described in detail in [21].
Trans-rectal Ultrasound (US) was used for real-time guidance, together with MRI and
often PSMA-PET/CT (Prostate Specific Membrane Antigen-Positron Emission Tomography/
Computated Tomography) for orientation via cognitive fusion. US/MRI fusion systems were
tested but discarded early on because they are inaccurate due to distortion of the prostate dur-
ing the IRE procedure, which prevents accurate image fusion. All treatments were carried out
with the NanoKnife (AngioDynamics Inc., USA). All treatment parameters are summarized in
Table 2A and 2B. All treatments were carried out within 24 hours with an overnight stay of the
patients.
Categorization of re-treatments
Of the 471 IRE-treatments, 43 were IRE-re-treatments after previous IRE (Table 2C). In this
section, the rationales for the re-treatments are explained and categorized.
1. Tumor extent/prostate-size related. IRE ablation volume is limited by 3 factors: maxi-
mal length of 1.5cm of the electrically conducting tip (“exposed length”) of the electrode, maxi-
mal distance between electrodes of 2 cm, and the total number of electrodes used, which for
Safty and efficacy of prostate cancer treatment with Irreversible Electroporation (IRE)
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most but a few exceptions we limited to 7, because more are very difficult to handle in the
restricted space of the perineum. The limited exposed length requires the electrodes to be re-
positioned from apex to base in larger ablations (“push-forward”); this severely limits visibility
on US by gas formation from electrolysis [20] such that more than one push-forward is almost
impossible. Thus, in very large cancers, which could not be completely ablated with a max. of 7
electrodes and one push-forward, the ablation was split into two IRE procedures.
2. Incomplete ablation/tumor residue. In this case, tumor residues were discernible
immediately after the IRE-procedure and were removed during a second IRE procedure.
Table 1. Patient demographics, cancer stage and grade. Most patients had intermediate to high risk cancers and a Gleason score of 7a (159) or 7b (66). Whilst organ-
confined cancers predominated (T1a –T2c, N = 313), 115 cases were non-organ confined (T3a –T4, approx. 27%). In 9 patients no Gleason score was available, as they had
refused biopsy. In four patients d’Amico risk classification was impossible due to lack of biopsy, whereas in five patients a PSA exceeding 20 ng/ml or clinical stage
of� T2c resulted in a high-risk classification.
Patient demographics Cancer stage and grade
Mean age /years 64 ± 8 D’Amico Risk Classification Gleason Score TNM Staging
Mean V of prostate /ml 32 ± 18 N/A 4 3+3 82 T1a-T1c 32
Mean PSA /ng/ml 10 ± 250 Low 25 3+4 / 4+3 225 T2a-T2c 281
# Patients with biopsy 420 Intermediate 88 4+4 68 T3a-T3b 54
# Patients with prior treatment� High 312 5+3 / 3+5 3 T4 and any with N1 and/or M1 61
Total no. of patients 429 D’Amico High Risk Group Sub-classes: > 4+4 42 N/A 1
“+1” “+2” “+3” N/A N/A 9
PSA 133 86 81 12
Gleason 48 100 164 0
Stage 10 20 281 1
�prior treatments are further explained in the text.
https://doi.org/10.1371/journal.pone.0215093.t001
Table 2. A. IRE treatment parameters of the presented patient cohort. B. Ablation field extent. C. Procedure cate-
gories of patients with more than one IRE application.
A. IRE Parameters
Total number of procedures 471
Total number of patients 429
Mean number of electrodes used 5 ± 1
Mean procedure time 120 ± 34 min
Mean set voltage-to-distance-ratio 1518.13 ± 204.05 V/cm
Mean ablated ablated /%� 72.4 ± 25.9%
B. Treatment Extent
Uni-lobar or focal (�50%) 123
Bi-lobar but not whole gland
(>50% and�90%)
153
Whole gland (>90%) 134
Cannot be determined or recurrence 63
C. Re-treatments categorized
Sum of re-treatments 43
Tumor extent/prostate-size related 8
Incomplete ablation/tumor residue 3
In-field recurrence 12
Out-of-field recurrence 16
Extra prostatic cancer (i.e. seminal vesicles) 3
�according to MRI evaluation 24h post IRE.
https://doi.org/10.1371/journal.pone.0215093.t002
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3. In-field recurrence. In this case, there was no discernible tumor mass immediately
after IRE but tumor re-growth 3 months or later in or adjacent to the IRE-ablation field. These
recurrences most likely occurred because the IRE-field did not encompass the whole extent of
the tumor.
4. Out-of-field recurrence. This type of "recurrence" occurred outside the IRE-ablation
field, in untreated prostatic tissue. In the proper sense, these were diagnostic failures, i.e.
missed macroscopic tumor foci due to sub-optimal diagnostic work-up (some patients refused
re-MRI and re-biopsy). Recurrent PCa outside a 1 cm range around the treatment field (i.e.
outside the border of the ablation zone) were considered as out-of-field failures.
5. Extra prostatic cancer. Patients with infiltrated seminal vesicles who had IRE treat-
ment were included in this patient cohort.
Follow-up
Inclusion cut-off date (date of IRE) and follow-up cut-off time for follow-up data inclusion
were determined such that a minimum follow-up time of 4 months resulted. Routine follow-
up comprised PSA-tests and MRI scans [21]. Whilst PSA-testing was recommended every 3
months in the first 2 years, then every 6m, MRI was recommended after 1 day, at 3, 6, 12
months post IRE, then annually. Biochemical recurrences were defined by a rise in PSA above
the baseline value at 3 months post IRE with confirmation by multi-parametric MRI, in some
cases by additional biopsy or PSMA-PET/CT. The matrix shown in Fig B in S1 Text summa-
rizes the resulting acquired data points. Additionally, patients were interviewed concerning
adverse events and their evolution over time. For long-term assessment of toxicity and func-
tional and oncological outcome, patients were grouped according to their maximum follow-
up time in order to have an objective result of the treatment progress (Table 3 and Fig A in S1
Text). Follow-up included mpMRI and/or PSA levels, as described in detail in S1 Text.
Assessment of safety
Acute toxicity was recorded intra- and post-operatively for all treatments until the time of
removal of the Foley catheter. All patients had an MRI 24h post IRE to confirm the congruence
Table 3. A. Follow-up period of all treated patients. B. Number of patients who completed the IIEF-5 Question-
naire. C. Number of patients who gave subjective feedback on their sexual functions. D. Number of patients who com-
pleted the IPSS-Questionnaire.
A. Follow-up Period B. IIEF-5-Questionnaire C. Subjective
Assessment of
ED
D. IPSS-Questionnaire
N total included 429 N total (with pre IRE
score)
294 N total
included
361 N total included 260
N at least one data
point
385 N pre and post IRE
with initial score > 7
155 N valid and complete input
with pre- and at least one
post- IRE score
155
N at least one follow-
up within 6m
344 N without adjuvant
therapies (i.e. HDT)
140
N at least one follow-
up between 6m and
12m
244 N all of the above and
valid/complete input
(included)
124 N valid input on quality of
life score pre- and at least
one post-IRE
125
N over 12m follow up 171 Median time to first/
last follow-up
129/
288
Median time to first/last
follow-up
101/
241
N last data
point� 12m
258
https://doi.org/10.1371/journal.pone.0215093.t003
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of the IRE-field with the extent of the tumor, and to assess potential procedure-related side
effects, e.g. hemorrhage and rectal damage.
Assessment of genitourinary function
Urinary continence was primarily assessed by interviewing the patients concerning any invol-
untary loss of urine related to the IRE-treatment and the different forms of incontinence (i.e.
stress-, urge, overflow-incontinence). If they affirmed incontinence, they were followed-up
more frequently, until the symptoms subsided. The International Prostate Symptom Score
(IPSS) was included in the evaluation process of toxicity and outcome after IRE treatment of
PCa, as it contains questions to urinary symptoms and one question concerning quality of life.
Table 3C summarizes the number of patients who completed the evaluation process. In addi-
tion to the International Consultation on Incontinence Questionnaire-Urinary Incontinence
(ICIQ-UI) assessments, continence status pre and post treatment and during the entire follow-
up period was assessed.
Erectile function (ED) was evaluated by two methods. Firstly, by the standard IIEF-5-Score
before and after IRE. Secondly, by our own evaluation algorithm, in which we asked patients
whether they 1) had experienced any negative change in erectile function related to IRE and 2)
were unable to have satisfactory intercourse (use of PDE-5 inhibitors was allowed, when
requested by the patient) and no spontaneous nocturnal erection. Patients in whom both 1
and 2 applied were classified as having an IRE-related significant ED. Table 3B and 3C summa-
rizes the number of patients who successfully completed the evaluation process.
Assessment of oncological outcome / recurrence free survival (RFS)
To measure oncological outcome, MRI and PSA were the primary and routine indicators for
the incident of recurrence, Choline or PSMA-PET/CT and re-biopsy were additionally
acquired when either PSA or MRI indicated a suspicious lesion (PI-RADS� 4). The PSA crite-
rium for recurrence were 3 consecutive PSA increases (ASTRO definition) [22], as the Nadir
required for the PHOENIX definition [23] was found difficult to assess after IRE, because fluc-
tuating and often decreasing PSA levels were observed in some cases even more than 9 months
after IRE in larger ablation zones. The MRI criterium for recurrence were in accordance with
the criteria defined in PI-RADS v1 (until 2016) and v2 (2016 onwards) [24]. The morphologi-
cal changes, diffusion coefficient, T2 and DCE changes were in accordance with the findings
recently published by Scheltema et al. [21]. All cases who were classified as potential recur-
rences according to the modalities outlined above or by other external sources that showed
suspicion or confirmation of a recurrence. All data was discussed by a board of urologists and/
or oncologists and radiologists who had at least 10 years of experience in the field. Conserva-
tively, biochemical recurrences were noted in cases where at least two strong indications, one
very strong indication or histological confirmation existed. The patient was then recom-
mended to undergo re-biopsy and, if positive for cancer, re-treatment if this was considered
the best choice for the patient.
Statistical analysis
Statistical analysis was performed using scripts written in Wolfram Research [https://www.
wolfram.com/mathematica/] Mathematica. The Wilcoxon-Mann-Whitney-Test was used to
assess statistically significant differences in paired continuous variables (all questionnaire out-
comes) and unpaired continuous variables (e.g. parameters concerning prostate volume and
involvement of neurovascular bundles), respectively. Analyses of regions of interest from
imaging were performed by means of OsiriX MD [https://www.osirix-viewer.com/osirix/
Safty and efficacy of prostate cancer treatment with Irreversible Electroporation (IRE)
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osirix-md/] and Merge eFilm Workstation [https://estore.merge.com/na/estore/content.aspx?
productID=444]. Statistical significance was set at p< 0.05. Kaplan-Meier curves and analysis
of oncological outcome was performed with Prism GraphPad 5 [https://www.graphpad.com/
scientific-software/prism/], with a confidence interval of 95%.
Results
Feasibility of the procedure
Tumor ablation with IRE was primarily successful in all treatments except three, which were
classified as in-field failures. Treatment field sizes are listed in Table 2B. In cases of IRE of recur-
rent PCa, treatment can possibly be hampered to varying degrees by scarring, calcifications and
distortions of the prostate, impeding US visibility and electrode insertion. IRE re-treatments
were only minimally hampered by anatomical distortion and poorer ultrasound visibility.
Toxicity
Relatively few adverse events occurred, mostly only mild to moderate (Table 4). Transient uri-
nary retention and/or dysuria were amongst the most common, both more frequent in large
prostates and/or large ablation zones. Permanent urinary retention occurred in 4 patients,
requiring TURP to restore normal urination. One of the first patients in this series developed a
recto-prostatic fistula (closing spontaneously after a few weeks), one patient experienced a
bladder perforation by a faulty catheter, and one patient suffered from prolonged urogenital-
tract infection, resulting in a testicular abscess which required orchidectomy; this infection
was not directly IRE-related since it occurred approx. 10 days after IRE after multiple compli-
cated catheter manipulations at an outside clinic, and was therefore excluded from the statis-
tics on continence and potency evaluation entirely but kept in the statistics on adverse events.
Urinary continence
In patients fully continent before IRE, no urinary incontinence was observed 12 months post
IRE or later during the observation period. Assessment was based on electrode position and
Table 4. Adverse events after IRE for PCa.
Mild 19.7%
Mild hematuria 3.8%
Transient urinary retention 9.1%
Dysuria 6.8%
Moderate 3.7%
Prostatitis 0.2%
Proctitis (uncertain genesis) 0.2%
Epididymiditis 0.6%
Pseudo post vasectomy syndrome 0.2%
Urinary tract infection 2.5%
Severe or medically significant 1.4%
Permanent urinary retention 0.8%
Recto-prostatic fistula 0.2%
Bladder perforation by catheter 0.2%
Severe prostatitis 0.2%
Life-threatening consequences 0%
Death related to adverse events 0%
https://doi.org/10.1371/journal.pone.0215093.t004
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24h post-procedure MRI, which showed edema and lack of contrast agent uptake. IPSS-Score
analysis revealed that in 7.7% of the evaluated patients scores increased temporarily from
below 8 to above 19 (severe symptoms) after IRE (Fig C in S1 Text). In one case, the last
included data point still showed a score above 20. In terms of urinary symptoms, 72.8% of eval-
uated patients reported no change or an improvement in quality-of-life, 27.2% a decrease. To
the date of data acquisition cut-off, the last available data point still shows dissatisfaction (� 5
points) in one patient who was initially satisfied (� 2 points).
Erectile function
Erectile function (EF) before and after IRE was evaluated in 124 patients with standard IIEF-5
questionnaires. Fourteen men (11.3%) developed severe erectile dysfunction (ED: IIEF5 >7
before IRE and IIEF5�7 after IRE), which persisted for longer than one year in four men
(3%).
Fig 1 shows the correlations of the IIEF-5-Score with ablation volume (1A), neurovascular
bundle (NVB) involvement (1B) and time post IRE (1C).
Fig 1A shows that smaller ablation volumes (<50% of the prostate) resulted in a mean
IIEF-5-Score reduction of 17.7% (-5.3 points), in whole-gland ablations (100% ablation vol-
ume) it was twice as high (37%, -11.1 points). Fig 1B shows that NVB involvement also corre-
lates positively with ED; assessment of NVB involvement in the treatment field was based on
the absence of contrast agent uptake on 24h post-IRE MRI. Fig 1C shows a statistically signifi-
cant improvement (p = 0.045) of EF over time (>18m post IRE): from a mean reduction of the
IIEF-5-Score of 33% (-8.72 points) during the first year after IRE, to 15% (-3.88 points) after
18 months. Thus, data shows a recovery of EF after IRE.
Subjective assessment revealed no reduction of EF in 52% and transient reduction of EF in
approximately 45% of all IRE treated patients (Fig 1D).
Efficacy–recurrence free survival
Oncological efficacy of IRE was determined by local tumor control or recurrence-free survival
(RFS). Recurrent PCa was determined by a rise in PSA value with corresponding findings on
mpMRI and/or PSMA-PET/CT (prostate specific membrane antigen positron emission
tomography). For details see supplement materials.
During the maximum follow-up period of 72 months, a total of 47 recurrent cancers
(approx. 10%) were detected. The data is summarized in the Kaplan-Meier-diagram in Fig 2.
As expected, most recurrences occurred in the high-grade and high-risk groups: 26 in the
Gleason>7 group (red curve, 60% RFS at 72m), 18 in the Gleason 7 group (orange curve, 85%
RFS at 72m). In the low-grade Gleason 6 group, 3 recurrences were observed (green curve,
94% RFS at 64m). It should be noted that all tumor re-occurrence, including those outside the
IRE treatment field, were considered recurrences here. Only 27 of the 47 PCas which were
classified as “recurrent” in Fig 2 occurred inside or at the margin of the IRE ablation zone, i.e.
were “true” in-field recurrences; the other 20 cases occurred in untreated prostate tissue out-
side the IRE ablation zone (out-of-field recurrences), mainly in patients who had not had 3D-
biopsy and/or endorectal mpMRI, i.e. in cases in which the diagnostic work-up was subopti-
mal. These should more appropriately be classified as diagnostic misses. The Kaplan-Meier-
diagram based on cases with recurrent PCa in or adjacent to the treatment field is shown in
Fig 3. Here, one patient had Gleason 6, 10 patients had Gleason 7a or 7b, and 16 patients had
Gleason>7.
In order to investigate whether the calculated Kaplan-Meier predictions of survival propor-
tions are not affected by follow-up times that are possibly too short, we selected all patients out
Safty and efficacy of prostate cancer treatment with Irreversible Electroporation (IRE)
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of the 27 patients with recurrent disease in or adjacent to the IRE treatment field who had fol-
low-up MRI/PSA of at least six months but no longer than 12 months before cut-off. The results
are shown in Fig D in S1 Text. For this purpose, we selected 16 patients, 1 Gleason 6, 7 Gleason
7 and 8 patients Gleason>7. Their recurrence free survival proportions at 3 years were 95%
(Gleason 6 green line), 90% (Gleason 7, orange line) and 53% (Gleason>7, red line).
Lastly, to better compare recurrence rates after IRE with those after RPE, we specifically
selected patients with organ confined disease (Fig E in S1 Text) out of all the 47 recurrences
(in-field and out-of-field recurrences). This resulted in 29 cases, with 2 Gleason 6, 15 Gleason
7 and 12 Gleason >7 patients. At 60 months follow-up, the survival proportions for IRE were:
95% for Gleason 6, 85% for Gleason 7 and 61% for Gleason >7.
Discussion
This retrospective analysis of 471 treatments of PCa with IRE, comprising all clinical stages
and recurrent disease, with over 6-year follow-up, to our knowledge constitutes as the largest
Fig 1. Erectile function after IRE for PCa. A. Correlation between IIEF5-Score reduction with the ablation volume: less than 50% of the prostate treated (left, purple,
-5.3 points), 50 to 90% of prostate volume ablated (middle, green, -7.73 points) and whole gland ablation (right, red, -11.1 points). B. Correlation between IIEF5-Score
reduction and extent of neurovascular bundle (NVB) involvement in the IRE-field. The columns show the most recently obtained mean IIEF5-Score (where approx. 2/3
were within the first year after IRE): no NVB (left, purple, -1.57 points), one (left or right) NVB (middle, green, -6.42 points) and both NVB (right, red, -10.52 points). C.
Reduction of the IIEF5-Score less than 18 months (left, red, -8.72 points) and more than one year after IRE (right, purple, -3.88 points). D. Outcome of subjective
assessment of erectile dysfunction (ED). 52% had no ED, 45% experienced transient ED (occurrence of reduction of ED within 1 year after IRE), and 3% experienced
persistent IRE-induced ED.
https://doi.org/10.1371/journal.pone.0215093.g001
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patient cohort with the longest observation time. Our data appears coherent with the data pre-
viously published but extends to higher grades and stages confirming that IRE is an effective
minimally-invasive procedure for the treatment of PCa.
The motivation to use IRE for the treatment of PCa was its promise of low invasiveness and
toxicity, with the goal of preservation of vital anatomical structures surrounding the prostate,
whose damage results in the urogenital functional deficits effected by surgery and radiation
therapy.
Due to the individualized treatments that were provided, the data is heterogeneous. Abla-
tion fields varied from focal to whole-gland, dependent on tumor stage, grade and distribution,
and personal preferences (Table 2). This limits specific conclusions, but clearly proves the
safety, scope and potential of IRE in a wide range of oncological manifestations.
Overall toxicity was low (Table 4), despite the fact that NVB, lower urinary sphincter
(LUS), rectum, and the base of the bladder were often at least partially included in the IRE-
field, mostly without lasting damage to these structures.
Most notable was the complete preservation of urinary continence after IRE in all patients,
despite the partial or total inclusion of the LUS in the IRE-field. Urinary symptoms improved
after IRE in patients with smaller IRE-fields, and slightly worsened for larger IRE-fields (Fig C
Panel B in S1 Text). The effect is clearly time-dependent, as the majority of men with IPSS--
Score elevation had decreased or disappearing symptoms after 12 months, on average even
decreased IPSS-Scores (Fig C Panel A in S1 Text). This is due to the fact that most treatment
Fig 2. Kaplan-Meier curves of recurrence free survival for PCa treated with IRE at 72 months follow-up; Gleason 6 (green), Gleason 7 (orange) and
Gleason>7 (red), with 95% CI (dashed thin lines). Recurrence-free survival rates were: Gleason 6: 94%, Gleason 7: 85%, Gleason>7: 60%. Number of
observations were: Gleason 6: 3, Gleason 7: 18, Gleason>7: 26. In this diagram, any tumor re-ocurrence, including those outside the IRE treatment field, was
included. Despite this conservative approach, which included PCa in untreated volumes of the prostate, the recurrence rates for high-grade (Gleason>7)
cancers fall inside the corridor of the recurrence rates after prostatectomy (obtained from the Han Tables of Johns-Hopkins) for comparable cancer stages and
PSA-levels (blue and magenta dots, CI shown as bars for ease of perception).
https://doi.org/10.1371/journal.pone.0215093.g002
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fields reduced part of the benign cellular hyperplasia of the transitional zone of the prostate
(BPH) but left the non-cellular elements (mainly fibers) in situ, which, when copious, can
obstruct urinary outflow.
Occurrence of ED after IRE in this series was rare, but not zero. Standard evaluation of ED
by IIEF-5 questionnaire revealed IRE-related severe ED in 11.3% of evaluated patients during
the first year (transiently), and in 3% 12 months after IRE. As assessment of EF is difficult due
to co-factors such as the nocebo effect [26], we also used our own subjective assessment
(Table 3 and Fig 1D). The results confirm the transient nature of ED after IRE, with 45% of
men experiencing transient ED (up to 12 months), but only 3% persistent severe ED, whilst
52% experiencing no ED at all.
Although frequently used, assessment of treatment toxicity on EF by standard criteria (i.e.
severe ED defined by IIEF-5 <7) does not provide the full picture. Evaluation of the changes
in the IIEF-5-Score as a function of time and ablation volume provides a more accurate pic-
ture. IRE-treatment induced a transient mean reduction of the IIEF-5-Score by 33%, and a
longer-term (>12 months) reduction by 15%. Thus, there is regeneration of erectile function
after IRE (Fig 1B, only the reduction in points plotted).
As to be expected, toxicity was clearly dependent on the size of the ablation zone and the
extent to which the NVB were involved: the mean reduction of the IIEF-5-Score was twice as
high in patients who had undergone whole-gland ablations (Fig 1A) as compared to smaller
Fig 3. Kaplan-Meier curves for recurrent PCa for Gleason 6 (green line), Gleason 7 (orange line) and Gleason> 7 (red line) with CI of 95% (dashed thin
lines in the associated colors), considering only the recurrences inside or at the margin of the IRE treatment field, excluding the 20 PCa which were
located within residual prostate tissue and thus classified as out-of-field recurrence. Compared to the Kaplan-Meier curves in Fig 2, this analysis is more
meaningful on the IRE technology specific aptitude for prostate cancer as it partly filters the diagnostic and focal therapy specific limitations. These were a total
of 27 cases, with 1 patient Gleason 6, 10 patients Gleason 7, and 16 patients Gleason> 7. Here the recurrence rates after IRE are more similar to the recurrence
rates after prostatectomy (values obtained from Han Tables [25], blue and magenta dots, CI shown as bars for ease of perception) for the lower stage cancers
(organ confined disease, blue), even lower at 5-year follow-up: Gleason 6: 98% (64 months), Gleason 7: 93% (72 months), Gleason>7: 75% (72 months).
https://doi.org/10.1371/journal.pone.0215093.g003
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ablation fields. Again, the effect is time-dependent, with mean reduction of IIEF5-Score cut-
ting half after 18 months (Fig 1B). Thus, there is regeneration after initial damage.
The correlation of toxicity with the size of the ablation zone is a complex matter. Especially
in large (= more than 4 electrodes) ablation zones, effects like Joule heating and electrolysis
overlap uncontrolled with the intended non-thermal IRE [20]. Larger treatment fields usually
translate to higher probability of involvement of anatomically critical structures around the
prostate which are important for urinary and erectile functions. Thermal IRE within these
structures will most likely cause transient or permanent impairment of their functionality.
Initial local tumor control was achieved in all IRE-treated patients. Excluding planned two-
stage treatments, recurrent rates of this patient cohort corresponds to an overall recurrence-
free survival (RFS) rate of 90% (Fig 2). This is well within the acceptable range of� 80%
according to a consensus meeting on focal therapy [27], even though recurrences which were
outside the treatment field were included and this cohort comprised many advanced high-risk
cancers.
Comparison of the recurrence rates with those after RPE (Figs 2 and 3 and D and E in S1
Text; magenta and blue dots obtained from the Han Tables of Johns-Hopkins [25]) yielded
similar results. For two reasons this should not be surprising: Firstly, local recurrences after
RPE are frequent even without positive surgical margins [25], caused by cancer cells spread
beyond the prostate. Secondly, IRE has been shown to reliably IRE kill all cells inside the treat-
ment field [16]. Thus, RFS only partially depends on the treatment method and to a large
extent on tumor biology in conjunction with the individual immune system [28]. There is,
however, a bias: After RPE, biochemical recurrences might be identified earlier than when
focal therapies are employed. Kaplan-Meier-curves presented here further showed a very simi-
lar slope as compared to the recently published data on 5-year outcomes of HIFU treatment
for PCa [10], The fact that our Kaplan-Meier-curves presented here further have showed a
very similar slopes as compared to the recently published data on 5-year outcomes of HIFU
treatment for PCa [10] indicates the higher effectiveness of IRE for PCa treatment compared
to HIFU, since the HIFU, even though their patient cohort comprised few high-risk and
advanced disease patients, whilst our cohort included many of those. only included very few
patients with advanced diseases and/or high Gleason Scores, whereas the results presented
here have a high number of patients with high risk disease. Our data on outcome of patients
with high-risk disease would thus be more comparable to [29], where Cryoablation was
employed to perform whole gland procedures. After 5 years, the clinical recurrence free sur-
vival rate was reported to be 69%–again very similar to our results.
Being retrospective, the significance of our data is limited to heterogeneity, incompleteness
and inconsistencies. One of our main concerns was that more patients with recurrences would
be lost to follow-up than patients without, presumably because they were disappointed with
IRE and turned towards RPE or RT. This might bias the data towards lower recurrence rates.
The opposite would also be conceivable: Patients without signs of a recurrence might avoid fol-
low-up because of inconvenience and cost. To test both hypothesis, we generated Kaplan-
Meier-curves only including patients who fulfilled the follow-up requirements (MRI+PSA) for
longer than one year and in whom the last complete follow-up was not older than one year
(Fig 3). The curve suggests that within the confidence intervals there is no significant differ-
ence in the mean “slope”, hence the drop-out-rates appear to be evenly distributed between
patients with and without recurrences.
Additionally, follow-up MRI and PSA scores had a median time till last follow-up data-
point of 12m, with accessible follow-up data of less than a year in approximately half of all
patients (Fig A in S1 Text). Fortunately, this fact does not result in a mean bias in the presented
Kaplan-Meier-curves, as the drop out group due to follow-up seems randomly distributed.
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However, with PCa being a slowly growing cancer follow-up periods need to be extended to
obtain a clearer understanding of oncological and functional outcomes.
In a clinical trial, re-biopsy would have been the standard follow-up method. In our series
of individualized treatments, most patients refused re-biopsy, unless a recurrence could not be
sufficiently ascertained by MRI and/or PSMA-PET/CT. Neither re-biopsy nor imaging are
completely accurate: both might miss recurrences (false negatives), imaging might overesti-
mate them (false positives, e.g. regenerative nodules and tracer accumulation in intra-prostatic
urine collections). It is, however, unlikely, to repeatedly miss a PCa of clinically relevant size
on MRI [9]. On the other hand, lesions below 5mm in size are unlikely to be missed by biop-
sies. We therefore concluded that MRI for small recurrences, and thus for recurrences in gen-
eral, MRI would have lower specificity at equal or higher sensitivity than biopsy [30]. Thus,
follow-up by PSA+MRI would be more likely to overestimate (false-positives) than underesti-
mate (false-negatives) the rate of recurrences. This is supported by a recent study carried out
by Scheltema et al. [21], which concludes that MRI is an accurate method to follow-up IRE-
treatments.
Conclusions
The retrospective evaluation of our data allows the conclusion that Irreversible Electroporation
(IRE) is a safe, effective and suitable modality for the treatment of PCa at all clinical stages and
recurrent disease. Treatment fields included the lower urinary sphincter, seminal vesicles, neu-
rovascular bundles and in some cases partially the rectum and bladder, yet overall toxicity was
low. Continence was preserved in all cases. In terms of local tumor control the comparison of
IRE with radical prostatectomy (RPE) revealed similar recurrence rates over time, suggesting
similar effectiveness of IRE to RPE. Thus the data illustrates the feasibility of IRE for PCa treat-
ments, with similar functional outcomes and short to midterm efficacy to RPE, but much lower
toxicity profile. Before IRE has the potential to become a new standard of care for the treatment
of PCa, the presented data needs to be confirmed by more systematic studies. A more stringent
evaluation is of course required, of which the multi-center registry (NCT02255890) is a first
step, as well as optimization and standardization of diagnostic work-up, patient selection, the
technical procedure of IRE and follow-up regime.
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